©NIJPP
Publications 2024

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY (NIJPP)

Volume 5 Issue 3 2024

https://doi.org/10.59298/NIJPP/2024/537110

Vaccines in the Era of Emerging Infectious Diseases: Immune Mechanisms and Innovations

Mangen Joshua Fred

Faculty of Pharmacy Kampala International University Uganda
Email: mangenjoshuafred@gmail.com

ABSTRACT

Emerging infectious diseases (EIDs) continue to challenge global public health, driven by factors like climate change, urbanization, and increasing human-animal interactions. The rapid spread of the COVID-19 pandemic highlighted the need for swift vaccine development and deployment. Vaccines remain one of the most effective public health tools, capable of preventing disease outbreaks by inducing immunity through humoral and cell-mediated mechanisms. Recent advancements in immunology and biotechnology have revolutionized vaccine development, enabling the creation of new platforms such as mRNA vaccines, viral vectors, and nanoparticle-based vaccines. These innovations allow for faster production, greater efficacy, and adaptability to novel pathogens. Additionally, new delivery methods, including microneedle patches and nasal sprays, aim to improve accessibility and ease of administration, particularly in low-resource settings. However, challenges such as vaccine equity, distribution logistics, and public hesitancy must be addressed to ensure broad and effective vaccination coverage. This review explores the immune mechanisms of vaccines, current vaccine technologies, and emerging innovations to address EIDs, with a focus on future preparedness for pandemics.

Keywords: Emerging infectious diseases, vaccines, mRNA technology, nanoparticle vaccines, immune mechanisms, vaccine innovations

INTRODUCTION

Emerging infectious diseases (EIDs) are a persistent threat to global health, driven by complex factors such as population growth, urbanization, environmental changes, climate change, and increasing human-animal interactions [1]. These conditions facilitate the transmission of zoonotic pathogens, leading to the emergence or re-emergence of diseases with pandemic potential. The COVID-19 pandemic dramatically highlighted how quickly an emerging virus can spread across the globe, overwhelming healthcare systems and causing unprecedented socio-economic disruption [2]. This crisis underscored the critical need for the rapid development and distribution of effective vaccines. Vaccines, which have long been central to public health, remain one of the most powerful interventions for preventing infectious diseases. They work by stimulating the immune system to recognize and respond to pathogens, providing both individual and herd immunity [3]. However, traditional vaccine development timelines are often too slow to respond effectively to rapidly spreading EIDs. To address this challenge, recent advances in immunology and biotechnology have led to innovative vaccine platforms that enable faster development, improved efficacy, and broader protection. This article explores the immune mechanisms vaccines utilize to elicit protection and reviews cutting-edge innovations in vaccine design, such as mRNA vaccines, nanoparticle vaccines, and new delivery systems, that hold promise for combating current and future emerging infectious diseases.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

Introduction to Vaccines and EIDs

Vaccines have historically been pivotal in controlling infectious diseases such as smallpox, polio, and measles [4]. However, the 21st century has seen a surge in EIDs, including severe acute respiratory syndrome (SARS), H1N1 influenza, Ebola, Zika virus, and, most recently, COVID-19 [5]. The capacity of infectious diseases to spread rapidly across the globe necessitates innovative approaches to vaccine development and deployment.

Immune Mechanisms in Vaccine Response

Vaccines work by mimicking natural infections, prompting the immune system to mount a defense without causing disease. They activate both innate and adaptive immunity.

Innate Immunity

Upon administration, vaccines interact with immune sensors like toll-like receptors (TLRs) that recognize pathogen-associated molecular patterns (PAMPs). This interaction induces the production of pro-inflammatory cytokines, chemokines, and other molecules, leading to the recruitment and activation of innate immune cells such as macrophages and dendritic cells [6]. These cells are crucial for antigen presentation to adaptive immune components. Adaptive Immunity Vaccines primarily aim to induce adaptive immunity, involving B cells (humoral immunity) and T cells (cell-mediated immunity).

Humoral Immunity (B Cells): The goal of most vaccines is to elicit the production of neutralizing antibodies by B cells [7]. These antibodies can prevent pathogens from entering host cells or neutralize toxins produced by the pathogen. Memory B cells, generated during the response, provide long-term protection by quickly producing antibodies upon re-exposure to the pathogen.

Cell-mediated Immunity (T Cells): T cells, particularly cytotoxic T cells, play a key role in killing infected cells. Some vaccines, especially those for intracellular pathogens like viruses, aim to generate strong T cell responses [8]. Memory T cells ensure a rapid and effective response upon subsequent exposures.

Types of Vaccines and Their Mechanisms

Several vaccine platforms have been developed over the years. These platforms vary in their composition, immunogenicity, and safety profiles, and each comes with unique strengths and challenges.

Live-attenuated Vaccines

Live-attenuated vaccines contain weakened forms of the pathogen that can still replicate but cause no or minimal disease. Examples include the measles, mumps, and rubella (MMR) vaccine and the yellow fever vaccine. These vaccines tend to elicit strong and long-lasting immune responses due to the replication of the attenuated pathogen, which stimulates both humoral and cell-mediated immunity. However, they are not suitable for immunocompromised individuals and carry the risk of reversion to a virulent form, though this is rare [9].

Inactivated Vaccines

Inactivated vaccines contain pathogens that have been killed or inactivated so that they can no longer replicate. Examples include the hepatitis A vaccine and the inactivated polio vaccine. These vaccines are safer for immunocompromised individuals because they cannot cause disease. Multiple doses or boosters may be needed to maintain immunity, and they typically induce weaker cellular immune responses compared to live-attenuated vaccines [10].

Subunit, Recombinant, and Conjugate Vaccines

These vaccines use pieces of the pathogen, such as proteins or sugars, to stimulate an immune response. Examples include the hepatitis B and human papillomavirus (HPV) vaccines. Since they do not contain live components, they are safer for immunocompromised people and have fewer side effects [11, 12]. They may require adjuvants and multiple doses to induce a strong and lasting immune response.

Nucleic Acid Vaccines (DNA/RNA Vaccines)

Nucleic acid vaccines introduce genetic material (DNA or mRNA) encoding the pathogen's antigens into the host cells, which then produce the antigen and trigger an immune response [13]. COVID-19 vaccines from Pfizer-BioNTech and Moderna are examples of mRNA vaccines. These vaccines can be developed quickly and induce both humoral and cell-mediated immunity [14]. mRNA vaccines, in particular, have shown remarkable efficacy and safety.DNA vaccines have faced challenges in human trials regarding efficient uptake into cells, though RNA vaccines have demonstrated better results. Cold storage requirements for some mRNA vaccines have also posed logistical issues.

Viral Vector Vaccines

These vaccines use a modified virus (usually non-pathogenic) to deliver genetic material encoding the antigen of the pathogen. The AstraZeneca and Johnson & Johnson COVID-19 vaccines are examples [15]. They elicit strong

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X
immune responses due to the viral vector's ability to replicate and present antigens in a natural infection-like context. Pre-existing immunity to the viral vector may limit the efficacy of the vaccine, and rare side effects, like clotting disorders, have raised concerns during the COVID-19 pandemic.

Innovations in Vaccine Development

The rapid development and deployment of COVID-19 vaccines have spurred a wave of innovation that could shape the future of vaccine development for EIDs.

mRNA Technology

One of the most significant breakthroughs in recent years has been mRNA vaccine technology. This platform allows for rapid vaccine design, manufacturing, and adaptation, as evidenced during the COVID-19 pandemic. mRNA vaccines do not require cultured cells or large-scale bioreactors, making production scalable. The adaptability of mRNA vaccines means they can be quickly modified to target new variants of a pathogen or entirely new pathogens [16]. Future applications may include vaccines for other viruses, bacterial infections, and even cancer immunotherapies [17, 18].

Self-amplifying RNA (saRNA) Vaccines

A step beyond traditional mRNA vaccines, self-amplifying RNA (saRNA) vaccines include additional RNA sequences that allow for the replication of the vaccine RNA once inside cells. This could enhance the vaccine's potency while requiring lower doses, reducing production costs and increasing availability [19].

Nanoparticle-based Vaccines

Nanotechnology is playing a crucial role in next-generation vaccines. Nanoparticle-based vaccines can deliver antigens more effectively and enhance the immune response by mimicking the structure of pathogens [20]. These vaccines offer high stability, and their modular nature makes it easy to adapt them to different diseases. The Novavax COVID-19 vaccine is an example of a nanoparticle-based approach.

Pan-Coronavirus and Universal Flu Vaccines

Given the frequent emergence of coronavirus variants and the ever-changing nature of the influenza virus, researchers are striving to develop "universal" vaccines. These vaccines aim to provide broad protection against multiple strains or species of viruses, reducing the need for frequent updates. The development of pan-coronavirus vaccines could help prevent future pandemics by targeting conserved regions of the virus across its variants [21, 22].

Vaccine Delivery Innovations

Innovative delivery methods, such as microneedle patches, nasal sprays, and oral vaccines, are gaining traction. These methods offer easier administration, enhance patient compliance, and reduce the need for cold chain storage, making vaccines more accessible, particularly in low-resource settings [23].

Challenges and Future Perspectives

While recent innovations have accelerated vaccine development, challenges remain. Emerging infectious diseases often require vaccines to be developed against novel pathogens, for which no prior knowledge or vaccine platforms may exist [24]. Additionally, public hesitancy toward vaccination, driven by misinformation, remains a significant barrier [25]. Vaccine equity is another critical challenge. Ensuring that vaccines reach low-income countries is essential to controlling pandemics globally [26]. Strategies like building regional manufacturing capacities and facilitating technology transfer will be key to addressing this issue.

CONCLUSION

Vaccines remain one of the most powerful tools in the fight against emerging infectious diseases. The rapid advancements in immune understanding and vaccine technology, such as mRNA platforms and nanoparticle vaccines, offer promising solutions to future pandemics. As global collaboration and innovation continue to evolve, the world is better positioned than ever to respond to the next infectious disease threat. In this era of emerging infectious diseases, the importance of vaccines cannot be overstated. The ongoing research and innovation are crucial for not only controlling current pandemics but also preparing for future health crises.

REFERENCES

1. Lindahl, J., & Grace, D. (2015). The consequences of human actions on risks for infectious diseases: a review. *Infection Ecology & Epidemiology*, 5.
2. Clemente-Suárez, V., Navarro-Jiménez, E., Moreno-Luna, L., Saavedra-Serrano, M., Jiménez, M., Simón, J., &Tornero-Aguilera, J. (2021). The Impact of the COVID-19 Pandemic on Social, Health, and Economy. *Sustainability*.

3. Laupèze, B., & Doherty, T. (2023). Maintaining a 'fit' immune system: the role of vaccines. *Expert Review of Vaccines*, 22, 256 - 266.
4. Ellebedy, A., & Ahmed, R. (2016). Antiviral Vaccines: Challenges and Advances. *The Vaccine Book*, 283 - 310.
5. Kumar, D., Batra, L., & Malik, M. (2020). Insights of Novel Coronavirus (SARS-CoV-2) disease outbreak, management and treatment. *AIMS Microbiology*, 6, 183 - 203.
6. Oliveira-Nascimento, L., Massari, P., &Wetzler, L. (2012). The Role of TLR2 in Infection and Immunity. *Frontiers in Immunology*, 3.
7. Huang, D., Tran, J., Olson, A., Vollbrecht, T., Guryleva, M., Tenuta, M., Fuller, R., Schiffner, T., Abadejos, J., Couvrette, L., Blane, T., Saye, K., Li, W., Landais, E., González-Martín, A., Schief, W., Murrell, B., Burton, D., Nemazee, D., & Voss, J. (2020). Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. *Nature Communications*, 11.
8. Igietseme, J., Eko, F., He, Q., & Black, C. (2004). Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens. *Expert Review of Vaccines*, 3, 23 - 34.
9. Lauring, A., Jones, J., &Andino, R. (2010). Rationalizing the development of live attenuated virus vaccines. *Nature biotechnology*, 28, 573 - 579.
10. Sabbaghi, A., Miri, S., Keshavarz, M., Zargar, M., &Ghaemi, A. (2019). Inactivation methods for whole influenza vaccine production. *Reviews in Medical Virology*, 29.
11. Fischer, N., Infante, E., Ishikawa, T., Blanchette, C., Bourne, N., Hoeprich, P., & Mason, P. (2010). Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis. *Bioconjugate chemistry*, 21 6, 1018-22.
12. Ellis, R. (1996). The new generation of recombinant viral subunit vaccines. *Current opinion in biotechnology*, 7 6, 646-52.
13. Vogel, F., & Sarver, N. (1995). Nucleic acid vaccines. *Clinical Microbiology Reviews*, 8, 406 - 410.
14. Ackerman, M., Henry, D., Finon, A., Binois, R., &Estève, É. (2021). Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine. *Journal of the European Academy of Dermatology and Venereology*, 35, e423 - e425.
15. Merkley, E., &Loewen, P. J. (2022). The correlates and dynamics of COVID-19 vaccine-specific hesitancy. *Vaccine*, *40*(13), 2020-2027.
16. Yu, M., Wang, N., Zhu, J., & Lin, Y. (2023). The clinical progress and challenges of mRNA vaccines. *Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology*, e1894.
17. Zhou, M., Tang, Y., Xu, W., Hao, X., Li, Y., Huang, S., Xiang, D., & Wu, J. (2023). Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies. *Frontiers in Immunology*, 14.
18. Guo, Z., Lu, B., Guo, Z., Giehl, E., Feist, M., Dai, E., Liu, W., Storkus, W., He, Y., Liu, Z., & Bartlett, D. (2019). Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. Journal for Immunotherapy of Cancer, 7.
19. Ballesteros-Briones, M., Silva-Pilipich, N., Herrador-Cañete, G., Vanrell, L., &Smerdou, C. (2020). A new generation of vaccines based on alphavirus self-amplifying RNA. *Current Opinion in Virology*, 44, 145 - 153.
20. Tornesello, A., Tagliamonte, M., Tornesello, M., Buonaguro, F., &Buonaguro, L. (2020). Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines. *Cancers*, 12.
21. Giurgea, L., Han, A., &Memoli, M. (2020). Universal coronavirus vaccines: the time to start is now. *NPJ Vaccines*, 5.
22. Vries, R., Altenburg, A., &Rimmelzwaan, G. (2016). Universal influenza vaccines: a realistic option? *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases*, 22 Suppl 5, S120-S124.
23. Kanekiyo, M., Ellis, D., & King, N. (2019). New Vaccine Design and Delivery Technologies. *The Journal of Infectious Diseases*, 219, S88 - S96.
24. Brisse, M., Vrba, S., Kirk, N., Liang, Y., & Ly, H. (2020). Emerging Concepts and Technologies in Vaccine Development. *Frontiers in Immunology*, 11.
25. Giannakou, K., & Vachtsioli, E. (2020). Understanding hesitancy around vaccines and vaccination: an umbrella review. *European Journal of Public Health.*

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

26. Patwary, M., Alam, M., Bardhan, M., Disha, A., Haque, M., Billah, S., Kabir, M., Browning, M., Rahman, M., Parsa, A., &Kabir, R. (2022). COVID-19 Vaccine Acceptance among Low- and Lower-Middle-Income Countries: A Rapid Systematic Review and Meta-Analysis. *Vaccines*, 10.

CITE AS: Mangen Joshua Fred (2024). Vaccines in the Era of Emerging Infectious Diseases: Immune Mechanisms and Innovations. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY, 5(3):7-11. https://doi.org/10.59298/NIJPP/2024/537110